Kiniksa Pharmaceuticals, Ltd. Total Assets | KNSA

Total Assets — these are all the resources owned by the business that have economic value. They are used to operate the business, generate profit, and ensure the company’s stability.

Main categories of assets
Current assets (used within one year):

Cash and cash equivalents
Accounts receivable (amounts owed by customers)
Inventory of goods, raw materials, and supplies
Short-term investments

Non-current assets (used for more than one year):

Fixed assets (buildings, machinery, equipment)
Intangible assets (brands, patents, software)
Long-term investments
Goodwill (reputational value from mergers)

Assets represent an objective measure of a business's value, reflecting everything behind it: physical infrastructure, technology, customer base, and financial resources. A high share of liquid assets such as cash indicates a company’s financial flexibility and its ability to maintain stability in changing market conditions.

Asset analysis helps assess how effectively a company utilizes its resources to generate revenue and profit, reflecting its operational efficiency and ability to convert invested capital into financial results.

Annual Total Assets Kiniksa Pharmaceuticals, Ltd.

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
764 M	581 M	526 M	460 M	233 M	349 M	255 M	322 M	47.5 M	56.5 M	-	-	-	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
764 M	47.5 M	359 M

Quarterly Total Assets Kiniksa Pharmaceuticals, Ltd.

2026-Q1	2025-Q3	2025-Q2	2025-Q1	2024-Q3	2024-Q2	2024-Q1	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
825 M	712 M	661 M	599 M	555 M	542 M	520 M	483 M	484 M	443 M	460 M	460 M	-	231 M	233 M	253 M	279 M	311 M	349 M	349 M	349 M	349 M	255 M	255 M	255 M	255 M	322 M	322 M	322 M	322 M	47.5 M	47.5 M	47.5 M	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
825 M	47.5 M	372 M

Total Assets of other stocks in the Biotechnology industry

Issuer	Total Assets	Price	% 24h	Market Cap	Country
AnaptysBio ANAB	317 M	$ 51.0	1.83 %	$ 1.48 B	USA
Allakos ALLK	96.6 M	-	-	$ 28.6 M	USA
Black Diamond Therapeutics BDTX	143 M	$ 1.88	0.53 %	$ 107 M	USA
Clovis Oncology CLVS	473 M	-	-7.23 %	$ 13 M	USA
Concert Pharmaceuticals CNCE	165 M	-	-	$ 401 M	USA
Evelo Biosciences EVLO	64.4 M	-	-14.46 %	$ 27.9 M	USA
BioMarin Pharmaceutical BMRN	7.59 B	$ 60.26	0.06 %	$ 11.6 B	USA
BioNTech SE BNTX	22 B	$ 98.52	0.24 %	$ 23.8 B	Germany
Can-Fite BioPharma Ltd. CANF	9.51 M	$ 2.17	0.46 %	$ 3.57 M	Israel
Freeline Therapeutics Holdings plc FRLN	86.6 M	-	-	$ 384 M	Britain
Genocea Biosciences GNCA	56 M	-	-15.0 %	$ 3.04 M	USA
Catalyst Biosciences CBIO	166 M	$ 13.99	0.84 %	$ 1.25 B	USA
C4 Therapeutics CCCC	359 M	$ 2.98	0.3 %	$ 247 M	USA
Codexis CDXS	148 M	$ 1.32	1.09 %	$ 115 M	USA
Amryt Pharma plc AMYT	816 M	-	-	$ 621 M	Britain
Cerus Corporation CERS	222 M	$ 2.62	0.38 %	$ 499 M	USA
G1 Therapeutics GTHX	122 M	-	-	$ 370 M	USA
Coherus BioSciences CHRS	258 M	$ 1.13	0.43 %	$ 132 M	USA
Celldex Therapeutics CLDX	583 M	$ 31.1	1.16 %	$ 2.07 B	USA
CollPlant Biotechnologies Ltd. CLGN	10.8 M	$ 4.25	3.16 %	$ 51.9 M	Israel
Cellectar Biosciences CLRB	15 M	$ 1.8	0.72 %	$ 4.69 M	USA
AbbVie ABBV	134 B	$ 264.34	0.09 %	$ 468 B	USA
Humanigen HGEN	11.2 M	-	-81.12 %	$ 4.28 M	USA
Cocrystal Pharma COCP	9.71 M	$ 1.17	1.74 %	$ 13.2 M	USA
AbCellera Biologics ABCL	1.36 B	$ 12.7	0.4 %	$ 3.79 B	Canada
Abeona Therapeutics ABEO	220 M	$ 5.4	2.65 %	$ 286 M	USA
Collegium Pharmaceutical COLL	1.66 B	$ 22.53	0.2 %	$ 713 M	USA
Corcept Therapeutics Incorporated CORT	837 M	$ 116.1	4.93 %	$ 12.1 B	USA
Фармсинтез LIFE	2.05 B	-	-	-	Russia
IGM Biosciences IGMS	266 M	-	-	$ 76.9 M	USA
IMV IMV	31.3 M	-	-	$ 13.1 M	Canada
Kinnate Biopharma KNTE	174 M	-	-	$ 123 M	USA
Cardiff Oncology CRDF	61.9 M	$ 1.24	0.74 %	$ 82.9 M	USA
Checkmate Pharmaceuticals CMPI	78.8 M	-	-	$ 231 M	USA
Corbus Pharmaceuticals Holdings CRBP	168 M	$ 7.14	0.19 %	$ 95.1 M	USA
Karuna Therapeutics KRTX	1.34 B	-	-	$ 12.2 B	USA
Curis CRIS	20 M	$ 0.83	1.1 %	$ 10.9 M	USA
CorMedix CRMD	826 M	$ 7.85	1.03 %	$ 565 K	USA
Crinetics Pharmaceuticals CRNX	1.13 B	$ 84.95	0.13 %	$ 7.99 B	USA
CRISPR Therapeutics AG CRSP	2.27 B	$ 54.23	0.23 %	$ 4.88 B	Schweiz
Champions Oncology CSBR	27 M	$ 4.9	0.1 %	$ 67.8 M	USA
Chimerix CMRX	146 M	-	-	$ 756 M	USA
Corvus Pharmaceuticals CRVS	71.1 M	$ 11.62	8.21 %	$ 918 M	USA
Cue Biopharma CUE	42.2 M	$ 31.41	1.45 %	$ 2.98 B	USA
CEL-SCI Corporation CVM	28.2 M	$ 1.67	2.38 %	$ 13.4 M	USA
Arbutus Biopharma Corporation ABUS	94.6 M	$ 4.85	0.2 %	$ 929 M	Canada
Cytokinetics, Incorporated CYTK	1.42 B	$ 64.66	0.17 %	$ 7.77 M	USA
Daré Bioscience DARE	32.5 M	$ 0.78	4.73 %	$ 8.72 M	USA
Adagene ADAG	78.3 M	$ 2.93	2.86 %	$ 173 M	China
DiaMedica Therapeutics DMAC	61.4 M	$ 7.94	1.4 %	$ 373 M	USA